Swiss drugmaker Roche's $2.4 billion deal for U.S.-based Foundation Medicine represents an increased bet on gene-guided treatments to fight cancers. The agreement represents a a 29% premium over the June 18 value of Foundation Medicine's shares.
USA TODAY, USA Today: Movies
Tue, 06/19/2018 - 5:12am
Swiss drugmaker Roche's $2.4 billion deal for U.S.-based Foundation Medicine represents an increased bet on gene-guided treatments to fight cancers. The agreement represents a a 29% premium over the June 18 value of Foundation Medicine's shares.